title: Small Bowel Adenocarcinoma.
abstract: Small bowel adenocarcinomas (SBAs) are rare tumors, but their incidence is increasing. The most common primary location is the duodenum. Even though SBAs are more often sporadic, some diseases are risk factors. Early diagnosis of small bowel adenocarcinoma remains difficult, despite significant radiologic and endoscopic progress. After R0 surgical resection, the main prognostic factor is lymph node invasion. An international randomized trial (BALLAD [Benefit of Adjuvant Chemotherapy For Small Bowel Adenocarcinoma] study) will evaluate the benefit of adjuvant chemotherapy. For metastatic disease, retrospectives studies suggest that platinum-based chemotherapy is the most effective treatment. Phase II studies are ongoing to evaluate targeted therapy in metastatic SBA.
authors.affiliation: Gastroenterology and Digestive Oncology Unit, Avicenne Hospital, HUPSSD, APHP, Université Paris 13, Sorbonne Paris Cité, 125 rue de Stalingrad, Bobigny 93000, France. Electronic address: thomas.aparicio@aphp.fr.
authors.forename: Thomas
authors.initials: T
authors.lastname: Aparicio
authors.affiliation: Gastroenterology and Digestive Oncology Unit, Georges Pompidou Hospital, APHP, Paris Descartes University, 20 Rue Leblanc, Paris 75015, France.
authors.forename: Aziz
authors.initials: A
authors.lastname: Zaanan
authors.affiliation: Gastroenterology and Digestive Oncology Unit, Avicenne Hospital, HUPSSD, APHP, Université Paris 13, Sorbonne Paris Cité, 125 rue de Stalingrad, Bobigny 93000, France.
authors.forename: Florence
authors.initials: F
authors.lastname: Mary
authors.affiliation: Oncology Unit, Saint Antoine Hospital, APHP, 184 Rue du Faubourg Saint-Antoine, Paris 75012, France.
authors.forename: Pauline
authors.initials: P
authors.lastname: Afchain
authors.affiliation: Hepato-Gastroenterology Unit, Dijon Hospital, 14 rue Paul Gaffarel, Dijon 21079, France.
authors.forename: Sylvain
authors.initials: S
authors.lastname: Manfredi
authors.affiliation: Translational Cancer Therapeutics department, The Beatson West of Scotland Cancer Centre, University of Glasgow, 1053 Great Western Road, Glasgow G12 0YN, UK.
authors.forename: Thomas Ronald Jeffry
authors.initials: TR
authors.lastname: Evans
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000235:genetics* / Q000378:metabolism / Q000628:therapy; D025601:Adenomatous Polyposis Coli Protein / Q000235:genetics; D053704:Capsule Endoscopy; D017024:Chemotherapy, Adjuvant; D013505:Digestive System Surgical Procedures; D058582:Double-Balloon Enteroscopy; D004379:Duodenal Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000378:metabolism / Q000628:therapy; D006801:Humans; D007414:Intestinal Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D007421:Intestine, Small; D009154:Mutation; D010641:Phenotype; D011379:Prognosis; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism; D012307:Risk Factors; D014057:Tomography, X-Ray Computed; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D051176:beta Catenin / Q000378:metabolism
chemical_list: D025601:Adenomatous Polyposis Coli Protein; D016283:Proto-Oncogene Proteins p21(ras); D018719:Erb-b2 Receptor Tyrosine Kinases; D016159:Tumor Suppressor Protein p53; D051176:beta Catenin; C555337:APC protein, human; C117307:KRAS protein, human; C495901:TP53 protein, human; C508053:ERBB2 protein, human
keywords: Carcinogenesis; Chemotherapy; Lynch syndrome; Prognostic factor; Rare tumor; Small intestine adenocarcinoma